The "Global Huntington's Disease Treatment Market Forecast Report by Drug Type (Approved Drugs, Off-label Drugs) End user (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy) Countries and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's offering.
Global Huntington's Disease Treatment Market is expected to grow beyond US$ 1.72 billion in the year 2032, up from US$ 436.0 million in 2023, with a CAGR of 16.54 percent from 2024 to 2032
This growth has been driven by a rise in the cases of Huntington's disease, the rise in need for more sophisticated approaches to managing the illness, and the innovations in newer treatment methods. A growing rate of prevalence of Huntington's disease across the globe is another factor that contribute to the market expansion. The consumption of medicines increases during earlier stages of the disease with increased outcome and awareness of the disease.
Enhanced effectiveness of diagnosing procedures and genetic tests help in early diagnosis and management. It also emphasises the increasing health care demand that Huntington's disease causes as well as encourages pharmaceutical innovation. Thus, the awareness of a growing number of sufferers who are looking for not only symptom relief but also therapy that can, directly or indirectly, influence the change of the disease course.
Research into Huntington's disease has yielded new therapeutic approaches
Recent research in Huntington's disease patient has led to the discovery of new therapeutic interventions like gene therapies that seek to suppress the mutant huntingtin protein that is characteristic of this disease. Such innovations can be seen to proactively alter the disease management's course and provide new forms of treatment. This benefit improves the care of patients and at the same time stimulates the development of the market through the appearance of new individualized and effective treatments. As these new therapies advance through the phases of clinical trials and approval the treatment for Huntington's disease will be meeting the un-met need of the global market and thus fueling growth in this domain.
The expanding pharmaceutical pipeline dedicated to Huntington's disease treatments
The availability of pipeline molecules that are still in the early stages of development for Huntington's disease will prove to be the driving force in the market progression. The market is still considered large and rewarding for such pharmaceutical companies, which, in turn, is encouraging them to invest more in their research and development divisions. All of the below-listed therapeutic pipelines include an appropriate mix of medicines for symptomatic management of Huntington's disease such as chorea, deteriorated cognitive abilities, and other disease-modifying treatments that address the fundamental cause of Huntington's disease.
The further development of these therapies is promising in improving patients' prognosis and acting on the well-being of those patients and their carers, who have many unmet needs. These novel therapies are to become available to patients after passing through phases of their trials and achieving regulatory stature to bring significant changes to the Huntington's therapeutic market in the future.
Asia Huntington's Disease Treatment Market
Huntington's disease treatment market is also experiencing growth in Asia due to several factors. Rising consciousness and detection rates in densely populated nations like China, India and Japan positively affect the need for the market. These nations are building up healthcare facilities and concentrating on neurodegenerative disorder treatment and diagnosis, thereby increasing the need for efficient solution. High spending on research and-development coupled with the favorable governmental policies ensure that pharmacy companies devise better therapies suitable for the different parts.
Moreover, increase in knowledge concerning genetics and diagnostics leads to better control of diseases and timely diagnosis of their symptoms. They could include the increasing costs in healthcare in advanced and developing nations as well as the increasing prevalence of chronic diseases; all are expected to increase the market of Huntington's disease in the Asia-Pacific region. In this ever-shifting environment, local & global biopharmaceutical companies have the chance to meet patients' abovementioned needs & enhance regional patient care.
Companies Featured
- H Lundbeck
- Pfizer Inc.
- Bausch Health Cos
- Teva Pharmaceutical Industries
- Dr Reddy's Laboratories
- Sun Pharmaceutical Industries Limited
- Hikma Pharmaceuticals Plc
- Alnylam Pharmaceuticals
- Novartis AG
- UniQure
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 170 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value (USD) in 2023 | $436 Million |
| Forecasted Market Value (USD) by 2032 | $1728 Million |
| Compound Annual Growth Rate | 16.5% |
| Regions Covered | Global |
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Huntington's Disease Treatment Market
6. Global Huntington's Disease Treatment Market - Share Analysis
6.1 By Drug Type
6.2 By End User
6.3 By Country
7. Drug Type
7.1 Approved Drugs
7.2 Off-label Drugs
8. End User
8.1 Hospital Pharmacy
8.2 Drug Store & Retail Pharmacy
8.3 Online Pharmacy
9. Countries
9.1 North America
9.1.1 United States
9.1.2 Canada
9.2 Europe
9.2.1 France
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Netherlands
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Malaysia
9.3.7 Indonesia
9.3.8 Israel
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Argentina
9.4.4 Colombia
9.5 Middle East & Africa
9.5.1 South Africa
9.5.2 Saudi Arabia
9.5.3 UAE
10. Key Players
10.1 Overview
10.2 Recent Development
10.3 Product Portfolio
10.4 Revenue
For more information about this report visit https://www.researchandmarkets.com/r/bxpcv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003213391/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
